• What Does a Gallbladder Cancer Organoid Medium Show?

  2026-10-21

  This article asks what a growth medium can—and cannot—show about human gallbladder cancer organoids. It explains how extracellular signals can affect cell survival, proliferation, differentiation, and three-dimensional architecture, while stressing that morphology or expansion is a composite readout rather than proof of tumor fidelity, mechanism, or therapeutic response.

• When G-1 Results Change Meaning

  2026-10-21

  A G-1 result is not a universal statement about GPER1 biology. Its meaning depends on whether the compound is being used as a receptor-activation probe, a comparator in a toxicity study, or part of a cell- or organ-level phenotype. The 2024 neuroblastoma study illustrates how molecular, pharmacological, and cytotoxic readouts can support different—but connected—claims.

• Calcium-Lactate Nanomedicine for CRC Immunity

  2026-10-20

  A literature-focused analysis of a calcium-lactate nanoparticle platform that combined bufalin, calcium-mediated stress, macrophage reprogramming and CD47-directed CRISPR/Cas9 delivery in colorectal cancer models. The findings support a mechanistically ambitious preclinical strategy, while the available evidence leaves important questions about editing efficiency, pyroptosis-specific attribution, systemic safety and clinical transferability.

• Trigonelline Hydrochloride: Evidence and Scope

  2026-10-19

  APExBIO identifies Trigonelline Hydrochloride as 1-methylpyridin-1-ium-3-carboxylic acid chloride and describes physicochemical properties and broad research applications. Without an identity-matched paper, those product claims support chemical identification and conceptual measurement context, but not a defined molecular target, pathway effect, efficacy claim, or study outcome.

• Arctigenin: Documented Mechanism and Evidence Scope

  2026-10-18

  APExBIO describes Arctigenin as a small molecule associated with NF-κB–iNOS pathway suppression, MEK1 inhibition, and additional in-vitro activities. Because no identity-matched research paper is available here, these claims should be treated as supplier-reported pharmacology rather than independently established efficacy or mechanism.

• Arctigenin: Mechanism Claims and Evidence Boundaries

  2026-10-17

  APExBIO describes Arctigenin as a stereochemically defined small molecule associated with NF-κB-linked iNOS suppression, MEK1 inhibition, kainate-receptor binding, and in-vitro HIV-1 replication inhibition. Because no identity-matched research paper or assay details are provided, the reported potencies and biological labels should be treated as supplier-attributed claims rather than independently validated findings.

• Arctigenin: Product Identity and Mechanistic Scope

  2026-10-16

  APExBIO describes Arctigenin (SKU N2399) as a research-use small molecule associated with NF-κB-linked iNOS suppression, MEK1 inhibition, kainate-receptor binding, and in-vitro HIV-1 replication effects. Those statements establish a catalog-level mechanism and scope, not independently verified efficacy, selectivity, or translational performance. No identity-matched primary study, comparator, model, sample size, uncertainty estimate, or independent replication is available in the provided evidence.

• (-)-Arctigenin: Product Identity and Evidence Limits

  2026-10-16

  APExBIO identifies Arctigenin, SKU N2399, as a small molecule associated with NF-κB/iNOS signaling, MEK1 inhibition, kainate-receptor binding, and in-vitro HIV-1 inhibition. Because no identity-matched paper or assay report is available, these mechanisms and potency values remain supplier-reported claims rather than independently validated findings.

• (-)-Arctigenin: MEK1 Inhibitor Evidence Limits

  2026-10-15

  APExBIO identifies Arctigenin (SKU N2399) as a stereochemically defined small molecule and attributes several activities to it, including inhibition of LPS-induced iNOS expression, MEK1 inhibition, kainate-receptor-associated neuroprotection, and in-vitro inhibition of HIV-1 replication. Because no identity-matched research paper is available, these statements should be treated as product-page claims rather than independently verified study findings. The reported IC50 values are assay-dependent and cannot establish selectivity, cellular exposure, clinical relevance, or broad antiviral activity.

• (-)-Arctigenin: Claims and Evidence Boundaries

  2026-10-15

  The APExBIO listing identifies Arctigenin as a defined small molecule and reports NF-κB/iNOS, MEK1, kainate-receptor, and HIV-1-related properties. Because no identity-matched primary study is available here, these claims should be treated as supplier-reported hypotheses rather than independently established biological findings.

• Neuroligin 1 Proteolysis and Social Memory

  2026-10-14

  Liu et al. identify a ventral-hippocampal mechanism in which social interaction promotes secretase-dependent Neuroligin 1 cleavage, producing an intracellular fragment that supports cofilin regulation, synaptic strengthening, and social-memory maintenance. The study provides convergent molecular, genetic, electrophysiological, structural, and behavioral evidence, while remaining distinct from Anisomycin and JNK-based apoptosis research.

• Exercise, EVs and Amyloid Clearance in AD Mice

  2026-10-14

  A 2026 Nature Aging study links exercise-related skeletal-muscle extracellular vesicles to microglial amyloid-beta clearance and improved cognition in Alzheimer’s disease mice. The findings support a preclinical muscle–brain communication mechanism, but they do not establish clinical efficacy or show that Methoxy-X04 was used in the study.

• UTP and Olfactory Receptor Gene Choice

  2026-10-13

  UTP Solution is a defined nucleotide reagent, whereas the cited olfactory study addresses epigenetic control of receptor-gene singularity. The evidence supports TRIM66 as a repressor of extra olfactory receptor genes, but it does not establish a direct role for UTP, exogenous nucleotide supplementation, or this supplier’s product in that mechanism.

• GW4064: What Comparisons Actually Show

  2026-10-13

  Existing evidence supports GW4064 as a non-steroidal FXR agonist research tool, but the supplied sources do not establish a direct comparison between GW4064 and oleanolic acid or demonstrate that it reproduces findings from cholestatic-injury models. The main evidence gaps concern comparator identity, model relevance, endpoint harmonization, and separation of FXR-dependent effects from broader pharmacology.

• Purmorphamine and Honeybee Olfaction: Evidence Limits

  2026-10-12

  Guo et al. reported that Smoothened-associated signaling correlates with olfactory-receptor expression, electrophysiological responses, and odor-guided behavior in Apis mellifera. The findings support a role for Smo in honeybee olfactory biology, but they do not establish a general therapeutic, osteogenic, or cross-species effect of Purmorphamine.

8577 records 1/572 page Next 12345 下5页 Last page